The Trump administration will exclude imported generic drugs from potential tariffs, bringing relief to pharmaceutical companies and Indian drugmakers who supply nearly half of U.S. generic prescriptions.

The dilated cardiomyopathy market is witnessing substantial growth, driven by advancements in cardiovascular therapies and the increasing incidence of the condition. Key factors contributing to the market's upward momentum include greater public awareness, government initiatives, and continuous progress in product innovation.

The specialty pharma sector is showing signs of stability, with modest growth and valuations recovering to historical averages. JP Morgan is most interested in Teva and Organon, maintaining a neutral rating on Teva due to its branded pipeline and caution about its U.S. generic business, while giving an underweight rating to Organon due to its recent stock price surge.

HCA Healthcare reported strong Q2 2024 results, with adjusted EPS of $5.50 beating estimates and revenues of $17.5 billion growing 10.3% year-over-year. The company benefited from rising admissions and higher inpatient and outpatient surgeries, though rising expenses partially offset the positives.

Amphastar Pharmaceuticals' stock has fallen 31% in 5 months despite positive financials, and whether it presents a value investment. Read more here.

Investors need to pay close attention to Amphastar (AMPH) stock based on the movements in the options market lately.

Amphastar (AMPH) delivered earnings and revenue surprises of 35.06% and 0.41%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Taysha Gene Therapies (TSHA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amphastar (AMPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amphastar (AMPH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

AMPH, BCML and DHC have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2024.

At the Needham Healthcare Conference, Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) highlighted why they remain excited about Baqsimi, the inhaled glucagon product for severe hypoglycemia.  Amphastar Pharmaceuticals develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products. Needham says the company still believes Baqsimi is the best glucagon product based on its expertise, which is difficult to genericize, and its IP that goes to 2036. Needham notes that the market opportunity for Baqsimi is promising because only a small fraction of insulin users currently receive a prescription for glucagon to manage emergency hypoglycemia.  There’s a widespread recommendation among doctors and guidelines that all insulin users should have access to ...Full story available on Benzinga.com